Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Skoulidis et al. (Fri,) studied this question.

www.synapsesocial.com/papers/69d96e6234ded318bb684332 — DOI: https://doi.org/10.1056/nejmoa2103695

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Frequency and Distinctive Spectrum of <i>KRAS</i> Mutations in Never Smokers with Lung Adenocarcinoma· 2008 · 564 citations
2. NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.· 2015 · 52 citations
3. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions· 2013 · 2,472 citations
4. <i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma· 2018 · 1,588 citations
5. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial· 2019 · 3,303 citations